Intra-Cellular Therapies, Inc. — Revenue by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/20a2dc44-5879-4aba-b8d5-a2db72c056b8/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2024 | $680.9M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-006993 |
| FY 2023 | $464.4M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-006156 |
| FY 2022 | $250.3M | 2022-01-01 – 2022-12-31 | evidence 0001193125-23-055176 |
| FY 2021 | $83.8M | 2021-01-01 – 2021-12-31 | evidence 0001193125-23-055176 |
| FY 2020 | $22.8M | 2020-01-01 – 2020-12-31 | evidence 0001193125-23-055176 |
| FY 2019 | $60.6k | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-057888 |
| FY 2017 | $245.8k | 2017-01-01 – 2017-12-31 | evidence 0001193125-19-054119 |
| FY 2016 | $330.7k | 2016-01-01 – 2016-12-31 | evidence 0001193125-19-054119 |
| FY 2015 | $91.4k | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-478475 |
| FY 2014 | $577.3k | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-089426 |
| FY 2013 | $2.7M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-114613 |
| FY 2012 | $3.1M | 2012-01-01 – 2012-12-31 | evidence 0001193125-14-114613 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Intra-Cellular Therapies, Inc. — all facts · Net Income · Operating Income